REFERENCES
- Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med. 1997;337:725–733.
- Yéni P, Hammer SM, Hirsh MS, et al. Treatment for adult HIV infection. 2004 Recommendations of the International AIDS Society-USA panel. JAMA. 2004;292:251–265.
- Gilbert P, DeGruttola V, Hammer SM, Kuritzkes DR. Viro-logic and regimen termination surrogate endpoints in AIDS clinical trials. JAMA. 2001;285:777–784.
- Mellors JW, Munoz A, Giorgi JV, et al. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infec-tion. Ann Intern Med. 1997;126:946–954.
- O'Brien TR, Blattner WA, Waters D, et al. Serum HIV-1 RNA levels and time to development of AIDS in the Multicenter Hemophilia Cohort Study. JAMA. 1996;276:105–110
- Mellors JW, Rinaldo CD Jr, Gupta P, et al. Prognosis in HIV-1 infection predicted by the quantity of virus plasma. Science. 1996;272:1167–1170.
- Coombs RW, Welles SL, Hooper C, et al. Association of plasma human immunodeficiency virus type 1 RNA level with risk of clinical progression in patients with advanced infection. J Infect Dis. 1996;174:704–712.
- O'Brien WA, Hartigan PM, Martin D, et al. Changes in plasma HIV-1 RNA and CD4+ lymphocytes counts and the risk of progression to AIDS. Veterans Affairs Cooperative Study Group on AIDS. N Engl J Med. 1996;334:426–431.
- Marschner IC, Betensky RA, DeGruttola V et al. Clinical trials using HIV-1 RNA based primary endpoints: statistical analysis and potential biases. J Acquir Immune Defic Syndr. 1999;20:220–227.
- Gilbert PB, Ribaudo HJ, Greenberg L, et al Considerations in choosing a primary endpoint that measures durability of virologic suppression in an antiretroviral trial. AIDS. 2000;14:1–12.
- Flandre P, Durier C, Descamps D, et al. On the use of magnitude of reduction in HIV-1 RNA in clinical trials: sta-tistical analysis and potential biases. J Acquir Immune Defic Syndr. 2002;30:59–64.
- Flandre P, Alcais A, Descamps D, et al. Estimating and comparing reduction in HIV-1 RNA in clinical trials using methods for interval censored data. J Acquir Immune Defic Syndr. 2004;35:286–292.
- Kelly PJ, Lim LL. Survival analysis for recurrent event data: an application to childhood infectious diseases. Stat Med. 2000;19:13–33.
- Pialoux G, Raffi R, Brun-Vézinet F, et al. A randomized trial of three maintenance regimens following three months of induction therapy with zidovudine, lamivudine and indinavir in naive HIV-1 infected patients. New Engl J Med. 1998;339:1269–1276.
- Lin DY, Wei U. The robust inference for the Cox propor-tional hazards model. J Am Stat Assoc. 1989;73:351–358.
- Prentice RL, Williams BJ, Peterson AV. On the regression analysis of multivariate failure time data. Biometrika. 1981;68:373–379.
- Descamps D, Flandre P, Calvez V, et al. Mechanisms of virologic failure in previously untreated HIV-infected pa-tients from a clinical trial of induction-maintenance therapy. JAMA. 2000;283:205–211.
- Flandre P, Peytavin G, Meiffredy V, et al. Adherence to antiretroviral therapy and outcomes in HIV-infected pa-tients enrolled in an induction/maintenance randomized trial. Antiviral Ther. 2002;7:113–121.
- Hughes JP. Mixed effects models with censored data ap-plications to HIV RNA levels. Biometrics. 1999;55:625–629.
- Jacqmin-Gadda H, Thiebaut R, Chene G, Commenges D. Analysis of left-censored longitudinal data with application to viral load in HIV infection. Biostatistics. 2000,1:355–368.